Ras Al Khaimah, UAE – Gulf Pharmaceutical Industries Company “Gulfar”, one of the leading pharmaceutical companies in the region, announced its financial results for the full year ending December 31, 2025.
It recorded strong growth in revenues and a noticeable improvement in profitability.
Upward path to profit
The company’s revenues amounted to AED 1,075.5 million, achieving a growth of 8.4% in the currency reported from ongoing operations compared to the previous year, and a growth of 9.0% on a fixed currency basis.
Profitability continued its stable upward trajectory, with net profit for the year reaching AED 173.3 million, “of which AED 111.2 million was exceptional one-time capital gain.”
This compares to AED 44.9 million in the previous year, “of which AED 37.6 million is exceptional one-time capital gain.”
Net operating profit from ongoing operations amounted to AED 43.9 million.
Reflecting an improvement in core business performance.
higher profits
EBITDA from continuing operations increased by 22.2% year-on-year to AED 109.4 million.
This highlights the successful implementation of strategic initiatives and the continuation of operational efficiency measures.
Julfar maintained a solid financial position, with total assets amounting to AED 1,779.8 million.
Shareholders’ equity amounted to AED 959.8 million.
Which supports the company’s continued growth and long-term strategic ambitions.
